RxDoctor Payments Data

Injung Kim

Adult Health · Fairfax, VANPI 1487095311

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.

$3,686in general payments, 2019–2025

Across 188 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$559
  • Gilead$545
  • Boehringer Ingelheim$431
  • AstraZeneca$417
  • Lilly USA, LLC$252
  • Amgen$203
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,679100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,686 in reported general payments places this provider in the 85th percentile of 368 adult health providers in Virginia.

See all adult health providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab55$94,444
TradjentaLinagliptin19$30,041
JanuviaSitagliptin Phosphate22$28,873
JardianceEmpagliflozin14$18,021
VemlidyTenofovir Alafenamide12$17,395
VascepaIcosapent Ethyl19$11,042
Lidocaine33$8,341
Atorvastatin Calcium414$2,168
Omega-3 Acid Ethyl Esters13$1,976
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,902
FenofibrateFenofibrate Nanocrystallized52$1,332
Rosuvastatin Calcium164$1,012
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide17$820
Amlodipine Besylate243$665
Pioglitazone Hcl65$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$203$94,44455 claims
Boehringer IngelheimTradjenta, Jardiance$431$48,06233 claims
GileadVemlidy$545$17,39512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 adult health providers in Virginia.

Other adult health in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →